CutiaTx

Cutia Therapeutics (SEHK: 2487) is a Shanghai-based, R&D-driven biopharmaceutical holding company founded in 2019 and dedicated to the dermatology treatment and care market. The company develops, manufactures, and commercializes a comprehensive suite of solutions for skin and scalp diseases using its proprietary CATAME® technology platform, targeting areas including scalp conditions, skin diseases, topical anesthesia, and localized treatments. Cutia went public on the Hong Kong Stock Exchange in June 2023 and employs approximately 304 people, with R&D, manufacturing, and commercial operations spanning Shanghai, Beijing, and Wuxi.